A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
← catalyst calendarSponsored by Camurus AB (industry) · CAMX.ST — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
72actual
Sites
63
Countries
Germany, Greece, Hungary +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-20
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-08-19 | actual | When the study began enrolling |
| Primary completion | 2023-05-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2023-05-02 | actual | The whole study's end, after follow-up |
| First posted | 2019-09-03 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-20 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acromegaly
Interventions
- Drug: CAM2029 (octreotide subcutaneous depot) — also filed as CAM2029
- Drug: Matching placebo — also filed as placebo
Primary outcome
what the primary-completion date above is the date OFProportion of Participants With Mean Insulin-like Growth Factor -1 (IGF-1) Levels ≤1 x Upper Limit of Normal (ULN) at Week 22/24
measured Week 22 and 24
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-01-31 · 1.9 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-02-08 · 1.2 MB · SAP_001.pdf
Publications
- PMID 40418492 — linked by the registry
- PMID 39378125 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CAMX.ST's whole pipeline · Catalyst calendar · Every registered study · What changed